Avalo scores Phase 2 success in comeback bid, raises $375M
Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an experimental drug ...
May 6, 2026 11:00 AM EDT FinancingR&D Avalo scores much-needed Phase 2 win and $375M raise as it attempts turnaround Max Gelman Senior Editor Avalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that